Abhinav K. Rao

Abhinav K. Rao

Auto-generated profile, based on publicly available information

Abhinav K. Rao

Digestive Disease Research Center, Medical University of South Carolina, Charleston, South Carolina, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KJKevan Josloff
Kevan Josloff
Jacob BeirigerJacob Beiriger
Jacob Beiriger
AKAdnan Khan
Adnan Khan
RGRichard J Gawel
Richard J Gawel
RKRichard Kirby
Richard Kirby
DHDina Halegoua-DeMarzio
Dina Halegoua-DeMarzio
Nonalcoholic Fatty Liver Disease (NAFLD) is a growing global phenomenon, and its damaging effects in terms of cardiovascular disease (CVD) risk are becoming more apparent. NAFLD is estimated to affect around one quarter of the world population and is often comorbid with other metabolic disorders including diabetes mellitus, hypertension, coronary artery disease, and metabolic syndrome. In this review, we examine the current evidence describing the many ways that NAFLD itself increases CVD risk. We also discuss the emerging and complex biochemical relationship between NAFLD and its common comorbid conditions, and how they coalesce to increase CVD risk. With NAFLD’s rising prevalence and deleterious effects on the cardiovascular system, a complete understanding of the disease must be undertaken, as well as effective strategies to prevent and treat its common comorbid conditions.

30 October 2024 in Brain & Heart
Verified
Journal Article
Open access
PDF file
MGMANJEET KUMAR GOYAL
MANJEET KUMAR GOYAL
SKShivam Kalra
Shivam Kalra
ARAbhinav Rao
Abhinav Rao
MKManisha Khubber
Manisha Khubber
AGAbhinav Gupta
Abhinav Gupta
AVAshita Rukmini Vuthaluru
Ashita Rukmini Vuthaluru
Neurological manifestations in inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, are increasingly recognized as significant contributors to both disease burden and patient morbidity. This comprehensive review delves into the spectrum of neurological complications linked with IBD, highlighting the involvement of both the central and peripheral nervous systems. The neurological impairments range from more common conditions such as peripheral neuropathy, characterized by nerve damage leading to pain and numbness, and cerebrovascular diseases, which include strokes and transient ischemic attacks, to less frequent but intensely severe conditions such as multiple sclerosis and myasthenia gravis, which involve the immune system attacking components of the nervous system. The complex pathophysiology underlying these manifestations integrates various factors including immune-mediated responses, vascular abnormalities such as thromboembolism, nutritional deficiencies often exacerbated by malabsorption and chronic inflammation, and the adverse effects elicited by IBD medications such as corticosteroids and immunomodulators. This review underscores the importance of adopting a multidisciplinary management approach. By integrating the expertise of gastroenterologists with that of neurologists, rheumatologists, and other specialists, patient outcomes can be significantly optimized. Further emphasis is placed on the necessity for heightened clinical awareness and the implementation of early diagnostic interventions to effectively identify and mitigate the neurological complications associated with IBD. In conclusion, ongoing research aimed at elucidating the underlying mechanisms that connect IBD with neurological disorders is imperative to facilitate the development of more effective preventative and therapeutic strategies for these challenging complications.

8 April 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
ARAbhinav K. Rao
Abhinav K. Rao
SKShivam Kalra
Shivam Kalra
DTDanny Tran
Danny Tran
APAngeli Patel
Angeli Patel
IAIbrahim Al-Saadi
Ibrahim Al-Saadi
BLBrett Van Leer-Greenberg
Brett Van Leer-Greenberg
INTRODUCTION: Multitarget stool DNA (MT-sDNA) tests (i.e., Cologuard) serve as screening tests for colorectal cancer (CRC) and are recommended by the US Preventive Services Task Force every 1–3 years. In this study, in a primary care setting, our aim was to evaluate the diagnostic performance of MT-sDNA testing and colonoscopy findings after a positive MT-sDNA testing result. METHODS: This was a retrospective cohort study of electronic health record data including all patients who underwent MT-sDNA tests (Cologuard; Exact Sciences, Madison, WI) at 35 network primary care facilities from Winter of 2019 to Spring of 2023. Patients who were at high risk and had a prior colonoscopy or prior negative MT-sDNA test result were excluded. Assessment of pathology was as previously described, including for advanced adenomas and CRC. RESULTS: Among the 5,827 patients for whom MT-sDNA testing was ordered, 3,119 patients completed the test; 482 (15%) had a positive MT-sDNA test, most of whom were women, had an average age of 65 years, and were predominantly White (Supplemental Figure 1, Table 1). Among these 482 patients, 277 (57%) had a follow-up screening colonoscopy, with 253 patients having complete colonoscopy data. Ten patients (4%) had CRC, 61 (24%) had advanced adenomas, and 184 patients (73%) had neither. The sigmoid colon was the most common site for CRC, with 8 of 10 patients having tumor, node, metastasis stage ≥1 CRC. DISCUSSION: The rate of colon cancer detection (10/5,827 [0.2%] patients for whom it was ordered and 10/3,119 [0.3%] who completed the test) was lower than expected in a screening cohort. Most patients who completed MT-sDNA testing had a false-positive result for advanced adenomas or CRC (73%). Together, these findings raise questions about the effectiveness of screening based on MT-sDNA testing in an average risk population.

17 April 2026 in The American Journal of Medicine
Verified
Journal Article
Closed access
ARAbhinav K. Rao
Abhinav K. Rao
AIAhmed Ibrahim
Ahmed Ibrahim
DRDon C. Rockey
Don C. Rockey

26 November 2023 in Cureus
Verified
Journal Article
Open access
PDF file
ARAbhinav K. Rao
Abhinav K. Rao
TATheshali Anthony
Theshali Anthony
NSNick Shaheen
Nick Shaheen
AKAidan Lum Kong
Aidan Lum Kong
IWIan G. Whitaker
Ian G. Whitaker
A 73-year-old male with hyperlipidemia and prior squamous cell carcinoma presented with a new-onset generalized tonic-clonic seizure and left-sided weakness. He had a progressively worsening cervical and occipital headache for nine days and was initially evaluated with an unremarkable CT head. The patient arrived at the emergency department with a left gaze deviation, prompting a "Code Neuro." CT angiography (CTA) detected a large dural sinus thrombosis, which was confirmed with a CT venogram and brain MRI. The patient was closely monitored in the intensive care unit and managed with heparin, nicardipine, and hypertonic saline boluses. Neurosurgery opted against surgical intervention. EEG revealed right hemisphere focal dysfunction. Recanalization occurred on hospital day 6. The patient was transitioned to apixaban upon discharge and instructed to follow up with hematology for a hypercoagulable workup. This case highlights the diagnostic complexity of cerebral venous sinus thrombosis (CVST), urging consideration of a differential even in atypical patients. We hope reporting this case will prompt clinicians to consider CVST in patients with non-specific symptoms, leading to timely diagnosis and treatment.

27 January 2025 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
ARAbhinav K Rao
Abhinav K Rao
TLThomas J Lee
Thomas J Lee
JBJeffrey Bodle
Jeffrey Bodle
As an emerging toxic recreational drug, kratom use has been associated with a range of adverse effects, but reports of structural changes in the central nervous system are rare. We report a case of a young man in his 20s with a history of anxiety and depression who presented with an altered mental status and anterograde and retrograde amnesia following kratom use. His labs showed elevated alanine aminotransferase and ammonia levels, and his MRI revealed bilateral hippocampal T2 hyperintensity signal changes. Following cessation of kratom and supportive care, the patient improved. This case highlights the importance of considering kratom as a potential cause of neurological symptoms in patients presenting with an altered mental status due to toxic ingestion.